# US 2016/0355568 A1 · Recombinant factor viii proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355568 A1
- Document ID: US20160355568A1
- Status: Published application
- Kind: A1
- Application number: 14/379,196
- Filed: 2013-02-15
- Published: 2016-12-08
- Earliest claimed: 2012-02-15
- Assignees: Biogen Idec MA Inc.
- Applicants: Biogen Idec Ma Inc.
- Inventors: John KULMAN
- Web page: https://patentgrep.com/patent/US20160355568A1

## CPC

- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 38/37: Factors VIII
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/43504: {from invertebrates}
- C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/76: Albumins
- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.

## Claims

### Claim 1

A recombinant FVIII protein comprising: a first polypeptide comprising Formula I: (A1)-a1-(A2)-a2-[B]; and a second polypeptide comprising Formula II: a3-(A3)-(C1);
wherein the first polypeptide and the second polypeptide are fused or exist as a heterodimer;
wherein, a) A1 is an A1 domain of FVIII; b) A2 is an A2 domain of FVIII; c) [B] is a B domain of FVIII, a fragment thereof, or is deleted; d) A3 is an A3 domain of FVIII; e) C1 is a C1 domain of FVIII; f) a1, a2, and a3 are acidic spacer regions;
wherein the A1 domain comprises a permissive loop-1 (A1-1) region and a permissive loop-2 (A1-2) region;
wherein the A2 domain comprises a permissive loop-1 (A2-1) region and a permissive loop-2 (A2-2) region;
wherein the A3 domain comprises a permissive loop-1 (A3-1) region and a permissive loop-2 (A3-2) region;
wherein at least one of the regions A1-1, A1-2, A2-1, A2-2, A3-1, A3-2, or a3 comprises a heterologous moiety; and
wherein the recombinant FVIII protein exhibits procoagulant activity.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the A1-1 region corresponds to a region in native mature human FVIII from about amino acid 15 to about amino acid 45 or from about amino acid 18 to about amino acid 41 of SEQ ID NO:1.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the A1-2 region corresponds to a region in native mature human FVIII from about amino acid 201 to about amino acid 232 or from about amino acid 218 to about amino acid 229 of SEQ ID NO:1.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the A2-1 region corresponds to a region in native mature human FVIII from about amino acid 395 to about amino acid 421 or from about amino acid 397 to about amino acid 418 of SEQ ID NO:1.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the A2-2 region corresponds to a region in native mature human FVIII from about amino acid 577 to about amino acid 635 or from about amino acid 595 to about amino acid 607 of SEQ ID NO:1.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the A3-1 region corresponds to a region in native mature human FVIII from about amino acid 1705 to about amino acid 1732 or from about amino acid 1711 to about amino acid 1725 of SEQ ID NO:1.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the A3-2 region corresponds to a region in native mature human FVIII from about amino acid 1884 to about amino acid 1917 or from about amino acid 1899 to about amino acid 1911 of SEQ ID NO:1.

### Claim at position 14

17-18. (canceled)

### Claim 19 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the heterologous moiety is inserted immediately downstream of an amino acid which corresponds to an amino acid in mature native human FVIII selected from the group consisting of: amino acid 18 of SEQ ID NO:1, amino acid 22 of SEQ ID NO:1, amino acid 26 of SEQ ID NO:1, amino acid 40 of SEQ ID NO:1, amino acid 188 of SEQ ID NO:1, amino acid 216 of SEQ ID NO:1, amino acid 220 of SEQ ID NO:1, amino acid 221 of SEQ ID NO:1, amino acid 224 of SEQ ID NO:1, amino acid 333 of SEQ ID NO:1, amino acid 336 of SEQ ID NO:1, amino acid 339 of SEQ ID NO:1, amino acid 399 of SEQ ID NO:1, amino acid 403 of SEQ ID NO:1, amino acid 409 of SEQ ID NO:1, amino acid 416 of SEQ ID NO:1, amino acid 442 of SEQ ID NO:1, amino acid 490 of SEQ ID NO:1, amino acid 599 of SEQ ID NO:1, amino acid 603 of SEQ ID NO:1, amino acid 1711 of SEQ ID NO:1, amino acid 1720 of SEQ ID NO:1, amino acid 1725 of SEQ ID NO:1, amino acid 1796 of SEQ ID NO:1, amino acid 1802 of SEQ ID NO:1, amino acid 1900 of SEQ ID NO:1, amino acid 1905 of SEQ ID NO:1, amino acid 1910 of SEQ ID NO:1, and any combination thereof.

### Claim 20 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the heterologous moiety is inserted into a3.

### Claim 21 (depends on 20)

The recombinant FVIII protein of claim 20, wherein the heterologous moiety is inserted into a3 immediately downstream of an amino acid which corresponds to amino acid 1656 of SEQ ID NO:1.

### Claim 22 (depends on 1)

The recombinant FVIII protein of claim 1, further comprising two, three, four, five, six, seven, eight, or nine additional heterologous moieties.

### Claim at position 19

23-25. (canceled)

### Claim 26 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the heterologous moiety comprises an element which increases the in vivo half-life of the protein, wherein the element is selected from:
(a) albumin;
(b) albumin-binding polypeptide;
(c) Fc;
(d) PAS;
(e) the C-terminal peptide (CTP) of the β subunit of human chorionic gonadotropin;
(f) polyethylene glycol (PEG);
(g) hydroxyethyl starch (HES);
(h) albumin-binding small molecules;
(i) a clearance receptor, or fragment thereof, wherein the clearance receptor blocks binding of the recombinant FVIII protein to FVIII clearance receptors;
(j) a low-density lipoprotein receptor-related protein 1 (LRP1) or a FVIII-binding fragment thereof; and
(k) any combination of (a)-(j).

### Claim at position 21

27-29. (canceled)

### Claim 30 (depends on 1)

The recombinant FVIII protein of claim 1, wherein the heterologous moiety comprises a peptide or polypeptide which enables visualization or localization of the recombinant FVIII protein, wherein the peptide or polypeptide which enables visualization or localization is selected from:
(a) a biotin acceptor peptide;
(b) a lipoic acid acceptor peptide;
(c) a fluorescent protein;
(d) GFP;
(e) RFP;
(f) YFP;
(g) EGFP;
(h) EYFP;
(i) a cysteine-containing peptide for ligation of a biarsenical dye or for conjugating metastable technetium;
(j) 4′,5′-bis(1,3,2-dithioarsolan-2-yl)fluorescein (FlAsH);
(k) a peptide for conjugating europium clathrates for fluorescence resonance energy transfer (FRET)-based proximity assays; and
(l) any combination of (a)-(k).

### Claim at position 23

31-39. (canceled)

### Claim 40 (depends on 1)

An isolated nucleic acid comprising a sequence encoding the recombinant FVIII protein of claim 1.

### Claim 41 (depends on 40)

An expression vector comprising the nucleic acid of claim 40.

### Claim 42 (depends on 40)

A host cell comprising the isolated nucleic acid of claim 40.

### Claim at position 27

43-44. (canceled)

### Claim 45 (depends on 42)

A method of producing a recombinant FVIII protein comprising culturing the host cell of claim 42 under conditions in which the recombinant FVIII protein is expressed.

### Claim 46 (depends on 1)

A composition comprising the recombinant FVIII protein of claim 1 and a pharmaceutically acceptable excipient.

### Claim 47 (depends on 46)

A method of preventing, treating, ameliorating, or managing a clotting disease or condition in a patient in need thereof by administering an effective amount of the composition of claim 46.

### Claim at position 31

48-110. (canceled)

### Claim 111 (depends on 41)

The expression vector of claim 41, wherein the vector is selected from;
(a) a plasmid;
(b) a phagemid;
(c) a virus;
(d) a retrovirus vector;
(e) an adenovirus vector;
(f) an adeno-associated virus vector;
(g) a SV40-type virus vector;
(h) a polyomavirus vector;
(i) an Epstein-Barr virus vector;
(j) a papilloma virus vector;
(k) a herpes virus vector;
(l) a vaccinia virus vector;
(m) a polio virus vector;
(n) a Moloney murine leukemia virus vector;
(o) a Harvey murine sarcoma virus vector;
(p) a murine mammary tumor virus vector;
(q) a Rous sarcoma virus vector; and
(r) any derivative thereof.
